Emerging Treatments in HIV

Once-Daily Raltegravir Safe, Effective for Initial HIV Treatment

Once-Daily Raltegravir Safe, Effective for Initial HIV Treatment

By

Once-daily regimens have been shown to improve adherence to treatment with no adverse effect on outcomes in patients with HIV.

EMERALD Trial: Week 48 Results Demonstrate Efficacy in Single-Tablet HIV Therapy

EMERALD Trial: Week 48 Results Demonstrate Efficacy in Single-Tablet HIV Therapy

By

Primary study end point was noninferiority of the single-tablet regimen vs control, related to virologic rebound, cumulative through week 48.

Bictegravir Co-Formulation Maintained High Levels of Virologic Suppression in HIV

Bictegravir Co-Formulation Maintained High Levels of Virologic Suppression in HIV

By

Phase 3 study assessed efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide from a multi-tablet regimen containing a boosted protease inhibitor regimen in virologically suppressed patients with HIV.

New Single-Tablet Treatment for HIV Infection Advantageous to Standard Therapy

New Single-Tablet Treatment for HIV Infection Advantageous to Standard Therapy

By

Virological response, efficacy, noninferiority, and tolerability were tested for bictegravir, emtricitabine, and tenofovir alafenamide vs dolutegravir, abacavir, and lamivudine.

FDA Grants Priority Review to Single Tablet HIV Regimen

FDA Grants Priority Review to Single Tablet HIV Regimen

By

The FDA has granted Priority Review to the New Drug Application for Gilead's investigational single-tablet regimen in the treatment of HIV-1 infection.

Amphotericin and Flucytosine Safe, Effective for HIV-Associated Cryptococcal Meningitis

Amphotericin and Flucytosine Safe, Effective for HIV-Associated Cryptococcal Meningitis

By

One-week amphotericin plus flucytosine was found to have comparable efficacy and safety profiles as the standard of care, 2-weeks amphotericin-based therapy, for treatment of HIV-associated cryptococcal meningitis in African patients.

Long-Acting Injectable Antiretrovirals for HIV Effective and Safe

Long-Acting Injectable Antiretrovirals for HIV Effective and Safe

By

The combination of long-acting intramuscular cabotegravir plus rilpivirine was demonstrated to be as effective as 3-drug daily oral ART for maintaining viral suppression of HIV-1 for up to 96 weeks in the LATTE-2 phase 2b study.

Efficacy, Safety of Fixed-Dose HIV Regimen With Bictegravir Evaluated

Efficacy, Safety of Fixed-Dose HIV Regimen With Bictegravir Evaluated

By

Gilead announced results from 2 Phase 3 studies for the investigational fixed-dose HIV regimen with bictegravir and emtricitabine for the treatment of treatment-naive adults with HIV.

Gilead Submits NDA for Triple-Therapy, Single Tablet HIV Regimen

Gilead Submits NDA for Triple-Therapy, Single Tablet HIV Regimen

By

Gilead submitted their single-tablet regimen containing bictegravir, emtricitabine, and tenofovir alafenamide for HIV-1 treatment to the FDA.

Pitavastatin Lowers Cholesterol More Effectively Than Pravastatin in HIV

Pitavastatin Lowers Cholesterol More Effectively Than Pravastatin in HIV

By

Pitavastatin reduced low-density lipoprotein cholesterol to a greater extent than pravastatin with a similar safety profile in patients with HIV and dyslipidemia.

Atazanavir/Ritonavir Plus Lamivudine Is as Safe, Effective as Triple Therapy

Atazanavir/Ritonavir Plus Lamivudine Is as Safe, Effective as Triple Therapy

By

Dual combination ART with atazanavir/ritonavir plus lamivudine demonstrated similar efficacy and safety as atazanavir/ritonavir plus 2 NRTIs at 48 weeks in the ATLAS-M trial.

Two HIV Studies Reinforce Guidelines Recommending TAF-Based Regimens

Two HIV Studies Reinforce Guidelines Recommending TAF-Based Regimens

By

Switching to TAF-based regimen was non-inferior to continuing TDF-based regimen in maintaining viral suppression.

Investigational 2-Drug HIV Regimen Showing Promise

Investigational 2-Drug HIV Regimen Showing Promise

By

Investigational combination of a once-daily 2-drug regimen of dolutegravir plus rilpivirine may be as effective as a 3- or 4-drug current antiretroviral regimen in HIV-1-infected patients.

Multiple Viral Load Value Testing May Better Inform HIV Transmission Potential

Multiple Viral Load Value Testing May Better Inform HIV Transmission Potential

By

Viral loads can fluctuate over time depending on patients' access and response to HIV treatment, their medication adherence behavior, and care status.

Potential New Drug Option for Treatment-Naïve HIV-1 Patients

Potential New Drug Option for Treatment-Naïve HIV-1 Patients

By

The once-daily dosing doravirine appears to have similar efficacy and to be non-inferior to once-daily ritonavir-boosted darunavir (DRV+r) on a background of 2 NRTIs in HIV-1 treatment-naïve adults.

Investigational HIV Monoclonal Antibody Effective in Multidrug-Resistant HIV-1

Investigational HIV Monoclonal Antibody Effective in Multidrug-Resistant HIV-1

By

New phase 3 results were reported from a single arm, multicenter study evaluating the safety and effectiveness of ibalizumab in patients infected with multidrug-resistant HIV-1.

Stribild HIV Post-Exposure Prophylaxis Brings Higher Completion Rate

Stribild HIV Post-Exposure Prophylaxis Brings Higher Completion Rate

By

HIV PEP preferred regimen Stribild seems to be a good option for immunocompetent people without HIV infection due to the ease of use and tolerable adverse effect profile.

Trends in Cancer That Can Complicate HIV Management

Trends in Cancer That Can Complicate HIV Management

By

Cancer prevention efforts for patients with HIV should focus on smoking cessation and appropriate screening based on recommendations for the general population.

Daily Pill Burden Decreasing for Patients With HIV

Daily Pill Burden Decreasing for Patients With HIV

Reduction in number of daily pills from 2005 to 2012; only 50.9% on BID regimen in 2012.

UNAIDS Officials Urge Fast Track Strategy For AIDS Response

UNAIDS Officials Urge Fast Track Strategy For AIDS Response

Reaching this target would see 90% of people living with HIV knowing their HIV status, 90% of people who know their HIV-positive status accessing treatment and 90% of people on treatment having suppressed viral loads by 2020.

Vitamin D Levels May Influence Immune Recovery in HIV Patients

Vitamin D Levels May Influence Immune Recovery in HIV Patients

Low vitamin D levels may hinder the efficacy of HIV treatment in adults, researchers from the University of Georgia reported.

IL-21 Therapy Repaired Immune Function in Primate SIV Research Study

IL-21 Therapy Repaired Immune Function in Primate SIV Research Study

Future study into IL-21 urged.

Molecule Shows Promise in Killing HIV-infected Cells

Molecule Shows Promise in Killing HIV-infected Cells

Molecule exposes latent HIV and broadly uses killer T cells to reduce HIV.

Tenofovir-Linked Acute Kidney Injury Noted in Patients With HIV

Tenofovir-Linked Acute Kidney Injury Noted in Patients With HIV

Fewer than half of patients with TFD-linked AKI had renal function recovery after drug withdrawal.

FDA Green Lights Genvoya to Treat HIV-1 Infection

FDA Green Lights Genvoya to Treat HIV-1 Infection

Medication contains a new form of tenofovir not previously approved by the FDA.

Statins Linked with Lower Liver Disease Progression in Patients with HIV and Hep C

Statins Linked with Lower Liver Disease Progression in Patients with HIV and Hep C

Statin use caused lower incidence of liver disease progression in HIV and HCV co-infected individuals.

Infants Born to Mothers Exposed to Certain HIV Drug May Have Lower Bone Mass

Infants Born to Mothers Exposed to Certain HIV Drug May Have Lower Bone Mass

According to a National Institutes of Health (NIH) Study, infants exposed in the womb to the HIV drug tenofovir disoproxil fumarate, may have lower bone mineral content than those exposed to other anti-HIV drugs.

WHO Guidelines Recommend Antiretrovirals for All with HIV

WHO Guidelines Recommend Antiretrovirals for All with HIV

By

The new guideline - released ahead of full publication later this year - notes that, in order to effectively implement the recommendations, countries will need to ensure that testing and treatment for HIV infection are readily available.

Opinion Piece Urges Continued Research into Infectious Diseases

Opinion Piece Urges Continued Research into Infectious Diseases

Seattle is a hub of infectious disease research.

FDA Approves Pediatric Labeling Update for Reyataz Oral Powder

FDA Approves Pediatric Labeling Update for Reyataz Oral Powder

The FDA has approved a pediatric labeling update for Reyataz (atazanavir) oral powder to include dosing recommendations for patients ≥3 months.

Sign Up for Free e-newsletters